Cantor Fitzgerald restated an overweight rating on shares, while J. Goldman & Co LP purchased a new stake in Annexon. Disclosure was made to the Securities and Exchange Commission.
1 report, 1 independent
Updated Aug 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald restated an overweight rating on shares, while J. Goldman & Co LP purchased a new stake in Annexon. Disclosure was made to the Securities and Exchange Commission.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- Cantor Fitzgerald and Citigroup issued rating updates, while MarketBeat reported research notes on Quince Therapeutics.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald reiterated an overweight rating on CleanSpark shares.
- Cantor Fitzgerald raised its price target and rating, while Bank of America adjusted its rating and price target, with MarketBeat aggregating the stock rating data.
- Cantor Fitzgerald initiated coverage with an overweight rating and price target for a company debuting on the New York Stock Exchange.